André Jefremow

[André Jefremow @anjefus]

@anatolitrabada receives Vedo mono. It will be interesting, if there is a sustained effect after one year (like VEGA or PROFILE).

[André Jefremow @anjefus]

@anatolitrabada The trial has several limitations ( e. g. mostly bio-naive patients) and the 8 week results are not that surprising. The safety profile is somehow surprising (no acne, no zoster, no lymphopenia?). However, what might be interesting will be the 12 months results: From W8 everybody

[Beatriz Gros @Bealoquebea]

I’ve just updated the last 2 years of this IBD trial timeline

I think it may be useful to gain perspective: decades of trial names together reminds us how much the field has evolved and how fast it is still moving

Now including >250 trials🤩
Full quality https://t.co/8YJktst9iP

[Jana G Hashash, MD, MSc @JHashashMD]

MUST READ📖
Joint @RomeFoundation & @IOIBD1 RAND/UCLA Recommendations for #Evaluation & #Managmt of #IBD with #IBS-like Symptoms @AGA_Gastro

https://t.co/TAfqa31eTZ

📝Nomenclature: IBD with IBS-like symptoms

Evaluation🩺 🧫

Therapies
🥗Diet
💊Drugs💉
🧠Brain gut behavioral tx

[André Jefremow @anjefus]

@ibdtweets That does not explain why the dosages of Risa (UC>CD) and Miri (CD>UC) differ regarding which disease needs a higher dosage.

[André Jefremow @anjefus]

@ibd_india I have talked with the company about this issue. They told me that upadacitinib is resorbed within two hours After taking the pill so it should be fine in most cases.

[Keith Siau @drkeithsiau]

One-off application of CAR T-cell therapy leads to long term remission for a range of autoimmune diseases including SLE and more recently, IBD. Is this game changing therapy in the making? #UEGWeek

[John Damianos, M.D. @john_damianosMD]

CAR T-cell therapy was effective for a patient with multi-drug refractory ulcerative colitis.

https://t.co/8uVPUiJW5W

[Jean-Frederic Colombel @JeanFredericCo1]

CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis | New England Journal of Medicine https://t.co/11SrU4A65K

[Tauseef Ali MD, FACG AGAF FACP @ibdtweets]

The gastroenterology and immunology communities are buzzing after a landmark NEJM publication (Sept 25, 2025) reported the first successful use of autologous CD19 CAR T-cell therapy in ulcerative colitis (UC). The patient, who had exhausted biologics and immunosuppressants, achieved sustained remission with mucosal healing—off all medications—for more than eight months.

So, what exactly is CAR-T, and why is this so exciting for IBD? 👇

[André Jefremow @anjefus]

@DrAkhilX Game breaker!

[Dominik Bettenworth @BettenworthDb]

Therapeutic B-cell targeting: the next big thing in #IBD treatment for selected pts? @RajaAtreya #MarkusNeurath

🌍✨ #Crohns #Colitis #MedTwitter
@IBD_FloMD @fgomollon @Y_ECCO_IBD @ibddoctor @IBDMD @DignassAxel @RestelliniS

https://t.co/tNJhbNINj4

[Udhayvir Grewal @UGrewalMD]

Cellular therapy is making big moves in so many spaces!! 🔥 🎯
In a patient with treatment-resistant ulcerative colitis, CD19 CAR T-cell therapy led to drug-free remission and mucosal healing, suggesting that B-cell targeting may offer a novel therapeutic pathway. @NEJM

https://t.co/jcKvwrBB4K

[Beatriz Gros @Bealoquebea]

Exciting times ahead 🥹

[André Jefremow @anjefus]

@GI_Pearls „One can argue that science, art, and ethics constitute the ultimate trifecta of medical practice“

Sapira‘s Art & Science of Bedside Diagnosis

[André Jefremow @anjefus]

@GI_Pearls Life‘s not always black and white and neither is the answer to the question. If there is nothing scientific then why ask this question at all? If we see science as a principle of investigation, medicine indeed is science.

[André Jefremow @anjefus]

@ebtapper 0. Vomiting

[André Jefremow @anjefus]

@OxytocinTussi @doc_khan454 @drkeithsiau Why at evening?

[André Jefremow @anjefus]

@drkeithsiau I read it, too. That was new for me, never heard it before. @EvidenceOpen gives a NNT of 50. I would have guessed a thousand or something.

[André Jefremow @anjefus]

@drkeithsiau Despite of the individuality of treatment response (e. g. previous treatment failures) I honestly doubt some of the numbers. For example, when you compare the weeks between IFX, 5-ASA und Aza, it seems far from real life experience. How did they come up with These numbers?